Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital, Norwich, UK.
Department of Trauma and Orthopaedics, Leicester Royal Infirmary, Infirmary Square, Leicester, UK.
Clin Endocrinol (Oxf). 2022 Nov;97(5):562-567. doi: 10.1111/cen.14798. Epub 2022 Jul 14.
Individuals with chronic hypoparathyroidism may experience suboptimal medical care with high frequency of unplanned hospitalisation and iatrogenic harm. In 2015 the European Society for Endocrinology published consensus guidelines on the management of chronic hypoparathyroidism. We set out to audit compliance with these guidelines.
Using these recommendations as audit standards we worked with the Society for Endocrinology and Parathyroid UK to conduct a national audit of management of chronic hypoparathyroidism in the United Kingdom. Endocrine leads in 117 endocrine departments were invited to participate in the survey by completing a data collection tool on up to 5 sequential cases of chronic hypoparathyroidism seen in their outpatient clinics in the preceding 12 months. Data were collected on 4 treatment standards and 9 monitoring standards. Data on hospitalisations and Quality of Life monitoring were also collected.
Responses were received from 22 departments giving a response rate of 19%, concerning 80 individual cases. The mean age of subjects was 48.4 years. The main findings were that the commonest cause of hypoparathyroidism was post surgical (66.3%). Treatments taken by the group included activated vitamin D analogues (96.3%), oral calcium salts (66.3%), vitamin D supplements (17.5%), thiazide diuretics (5%) and rhPTH (1.3%). Compliance with the audit standards varied between 98.8% and 60% for the treatment standards and between 91.3% and 20% for the monitoring standards. Some of the areas of weakness revealed include low rates of 24 h urinary calcium excretion monitoring, serum magnesium monitoring and low rates of renal imaging where indicated. In addition and importantly, 16.3% of subjects had experienced at least one hospital admission in the preceding 12 months.
We conclude that further improvements in the UK national standard of management of chronic hypoparathyroidism should be made and that this will benefit both quality of life, morbidity and potentially mortality in this group of patients.
患有慢性甲状旁腺功能减退症的个体可能会经历医疗服务不佳,频繁出现计划外住院和医源性伤害。2015 年,欧洲内分泌学会发布了慢性甲状旁腺功能减退症管理的共识指南。我们着手审核这些指南的执行情况。
我们使用这些建议作为审核标准,与内分泌学会和英国甲状旁腺学会合作,对英国慢性甲状旁腺功能减退症的管理进行了全国性审核。邀请了 117 个内分泌部门的内分泌负责人通过填写一份数据收集工具,对过去 12 个月在其门诊就诊的 5 例连续慢性甲状旁腺功能减退症患者进行调查。数据收集了 4 项治疗标准和 9 项监测标准。还收集了住院和生活质量监测的数据。
收到了 22 个部门的回复,回复率为 19%,涉及 80 个单独的病例。受试者的平均年龄为 48.4 岁。主要发现是甲状旁腺功能减退症最常见的病因是手术后(66.3%)。该组服用的药物包括活性维生素 D 类似物(96.3%)、口服钙剂(66.3%)、维生素 D 补充剂(17.5%)、噻嗪类利尿剂(5%)和 rhPTH(1.3%)。治疗标准的符合率在 98.8%到 60%之间,监测标准的符合率在 91.3%到 20%之间。发现的一些薄弱环节包括 24 小时尿钙排泄监测、血清镁监测和在需要时进行肾脏成像的比例较低。此外,重要的是,16.3%的患者在过去 12 个月至少经历过一次住院治疗。
我们得出结论,英国慢性甲状旁腺功能减退症管理的国家标准应进一步提高,这将有利于改善该组患者的生活质量、发病率,甚至死亡率。